Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
about
Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of IkarosProtein kinase inhibitors against malignant lymphomaSYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.Nanopharmacology in translational hematology and oncologyCD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATORLiposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in MiceNanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemiaTargeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.The Syk kinase as a therapeutic target in leukemia and lymphoma.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.Hedgehog pathway inhibitors: a patent review (2009--present).Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
P2860
Q24301012-AC8C0188-3D8A-4456-8FA6-F8F6629F8282Q27024212-163C6C9E-992B-471D-AA40-0627F462D9EBQ33631405-F160DFE0-67F4-4F23-A6A0-39ED77D1BBE5Q33961538-C198B5D1-5B63-4FCF-A8C2-0F69874074AAQ34154532-5B27C35C-76B9-4D50-B278-8437C11D79FFQ34653474-C901FC1A-7A0A-4610-AC36-EC002939AB19Q35949248-C3FD68D7-878F-4902-8160-020DC806967FQ36873283-5611C89E-DE9F-429F-B5B6-D0E2026E71E4Q36889248-39E4734C-1E2E-411B-8858-17AF67A6829CQ37857853-B0D934F2-0A23-4C49-B4BC-6D815524234EQ38011765-CD69349B-56E7-43B1-A0D7-CCDA7BC58FE0Q38072095-1861CD98-4A40-4F22-8D9C-BF192CC4AAE9Q38097334-8BABF81C-CBD2-44E0-8179-C2616DE85A65Q45982703-B6271BDA-7B98-46E1-AAE2-0E61BB442568Q46134516-595089EC-6032-4482-82C0-658D4CA63E5BQ54465339-5A389AA6-0F88-4E56-A5D4-BB03184F2CCDQ54979889-EE49B687-DDB3-4978-8BD1-A7AC473781FC
P2860
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@en
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@nl
type
label
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@en
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@nl
prefLabel
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@en
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@nl
P2860
P356
P1476
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
@en
P2093
Sanjive Qazi
P2860
P304
P356
10.1586/ERA.10.112
P577
2010-09-01T00:00:00Z